PPMS
MCID: PRM108
MIFTS: 46

Primary Progressive Multiple Sclerosis (PPMS) malady

Categories: Neuronal diseases, Genetic diseases

Aliases & Classifications for Primary Progressive Multiple Sclerosis

Aliases & Descriptions for Primary Progressive Multiple Sclerosis:

Name: Primary Progressive Multiple Sclerosis 12 52 14
Multiple Sclerosis, Primary Progressive 69
Primary-Progressive Ms 12
Ppms 12

Classifications:



External Ids:

Disease Ontology 12 DOID:0050784
MeSH 42 D020528
SNOMED-CT 64 428700003
UMLS 69 C0751964

Summaries for Primary Progressive Multiple Sclerosis

Disease Ontology : 12 A multiple sclerosis that is characterized by steady worsening of neurologic functioning, without any distinct relapses or periods of remission. The rate of progression may vary over time, with occasional plateaus or temporary improvements, but the progression is continuous.

MalaCards based summary : Primary Progressive Multiple Sclerosis, also known as multiple sclerosis, primary progressive, is related to mental retardation, x-linked, syndromic 13 and jamaican vomiting sickness. An important gene associated with Primary Progressive Multiple Sclerosis is IFNB1 (Interferon Beta 1), and among its related pathways/superpathways are Innate Immune System and Cytokine Signaling in Immune system. The drugs 4-Aminopyridine and Everolimus have been mentioned in the context of this disorder. Affiliated tissues include brain, lymph node and spinal cord, and related phenotypes are hematopoietic system and cellular

Related Diseases for Primary Progressive Multiple Sclerosis

Diseases in the Primary Progressive Multiple Sclerosis family:

Multiple Sclerosis 4 Multiple Sclerosis 3
Multiple Sclerosis 2 Multiple Sclerosis 5
Secondary Progressive Multiple Sclerosis

Diseases related to Primary Progressive Multiple Sclerosis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 107)
id Related Disease Score Top Affiliating Genes
1 mental retardation, x-linked, syndromic 13 11.7
2 jamaican vomiting sickness 11.0
3 pyridoxal 5'-phosphate-dependent epilepsy 10.3 IL10 TNF
4 tubular renal disease-cardiomyopathy syndrome 10.3 IL10 TNF
5 lagophthalmos 10.3 IL10 TNF
6 multiple vertebral anomalies unusual facies 10.3 IL10 TNF
7 parovarian cyst 10.2 IFNB1 TNF
8 conidiobolomycosis 10.2 IL10 TNF
9 chordoid meningioma 10.2 IL10 MMP9 TNF
10 burns 10.2 IL10 MMP9 TNF
11 infancy electroclinical syndrome 10.2 IL10 MMP9 TNF
12 neurotic disorder 10.2 ICAM1 IL10 TNF
13 conduct disorder 10.2 ICAM1 IL10 TNF
14 microcephaly 10.2 ICAM1 IL10 TNF
15 acquired polycythemia 10.2 ICAM1 IL10 TNF
16 tuberculosis 10.2 IFNB1 IL10 TNF
17 neonatal hypoxic and ischemic brain injury 10.2 IL10 MMP9
18 balkan nephropathy 10.2 ICAM1 IL10 TNF
19 xanthogranulomatous cholecystitis 10.2 ICAM1 IL10 TNF
20 amelogenesis imperfecta 10.2 ICAM1 IL10 TNF
21 pyelonephritis 10.2 ICAM1 IL10 TNF
22 benign eccrine breast spiradenoma 10.2 ICAM1 IL10 TNF
23 parasitic protozoa infectious disease 10.2 ICAM1 IL10 TNF
24 hyperuricemia, pulmonary hypertension, renal failure, and alkalosis 10.2 IL10 MMP9 TNF
25 nonspecific interstitial pneumonia 10.2 ICAM1 IL10 TNF
26 geniculate ganglionitis 10.2 ICAM1 IL10 TNF
27 pulmonary eosinophilia 10.2 IL10 MMP9 TNF
28 sclerosing adenosis of breast 10.2 ICAM1 IL10 TNF
29 endosalpingiosis 10.2 IL10 TNF
30 developmental coordination disorder 10.2 CSF1R MMP9
31 nervous system cancer 10.2 IL10 MMP9 TNF
32 gastric dilatation 10.2 IL10 MBP TNF
33 esophageal candidiasis 10.2 ICAM1 IL10 TNF
34 severe combined immunodeficiency, t cell-negative, b-cell/natural killer-cell positive 10.1 IL10 TNF
35 intratubular embryonal carcinoma 10.1 IL10 MMP9 TNF
36 non-gestational choriocarcinoma 10.1 IFNB1 IL10 MBP
37 cervical adenoid basal carcinoma 10.1 IL10 MBP MOG
38 status epilepticus 10.1 MBP MOG TNF
39 neonatal stroke 10.1 IL10 MBP TNF
40 right ventricle hypoplasia 10.1 ICAM1 TNF VCAM1
41 optic nerve hypoplasia 10.1 ICAM1 IL10 MMP9 TNF
42 peripheral artery disease 10.1 IL10 TNF VCAM1
43 acute chest syndrome 10.1 ICAM1 IL10 MMP9 TNF
44 alopecia-intellectual disability syndrome 10.1 MBP MOG PLP1
45 root caries 10.1
46 hypopyon ulcer 10.1 ICAM1 VCAM1
47 epidermolysis bullosa simplex, sutosomal recessive 2 10.1 ICAM1 MMP9 VCAM1
48 asbestosis 10.1 IL10 TNF VCAM1
49 macrodactyly of the foot 10.1 ICAM1 VCAM1
50 respiratory system disease 10.1 IL10 TNF VCAM1

Graphical network of the top 20 diseases related to Primary Progressive Multiple Sclerosis:



Diseases related to Primary Progressive Multiple Sclerosis

Symptoms & Phenotypes for Primary Progressive Multiple Sclerosis

MGI Mouse Phenotypes related to Primary Progressive Multiple Sclerosis:

44 (show all 12)
id Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.22 CSF1R ICAM1 IFNB1 IL10 IL7R MBP
2 cellular MP:0005384 10.21 CSF1R ICAM1 IL10 IL7R MBP MMP9
3 homeostasis/metabolism MP:0005376 10.2 MMP9 OMG PLP1 S100B TNF VCAM1
4 immune system MP:0005387 10.17 CSF1R ICAM1 IFNB1 IL10 IL7R MBP
5 growth/size/body region MP:0005378 10.15 CSF1R ICAM1 IL10 MBP MMP9 MOG
6 nervous system MP:0003631 9.97 MOG PLP1 TNF CSF1R ICAM1 IFNB1
7 muscle MP:0005369 9.88 ICAM1 IL10 MMP9 MOG PLP1 TNF
8 neoplasm MP:0002006 9.85 ICAM1 IFNB1 IL10 IL7R MMP9 TNF
9 no phenotypic analysis MP:0003012 9.73 CSF1R IFNB1 IL10 OMG TNF VCAM1
10 normal MP:0002873 9.7 CSF1R IFNB1 IL10 IL7R MBP OMG
11 reproductive system MP:0005389 9.5 MMP9 PLP1 TNF VCAM1 CSF1R IL10
12 vision/eye MP:0005391 9.17 TNF ICAM1 IL10 MBP MMP9 MOG

Drugs & Therapeutics for Primary Progressive Multiple Sclerosis

Drugs for Primary Progressive Multiple Sclerosis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 268)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
4-Aminopyridine Approved Phase 4,Phase 3 504-24-5 1727
2
Everolimus Approved Phase 4 159351-69-6 6442177
3
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
4
Mycophenolate mofetil Approved, Investigational Phase 4 128794-94-5 5281078
5
Mycophenolic acid Approved Phase 4 24280-93-1 446541
6
Procaine Approved, Investigational, Vet_approved Phase 4 59-46-1 4914
7
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
8
Tacrolimus Approved, Investigational Phase 4,Phase 2 104987-11-3 445643 439492
9
Interferon beta-1b Approved Phase 4,Phase 3,Phase 2 145155-23-3
10
Dopamine Approved Phase 4,Phase 2,Phase 1 51-61-6, 62-31-7 681
11
Dimethyl fumarate Approved, Investigational Phase 4,Phase 3,Phase 2 624-49-7 637568 5271565
12
Interferon beta-1a Approved, Investigational Phase 4,Phase 3 145258-61-3 6438354
13
Gabapentin Approved, Investigational Phase 4,Phase 2 60142-96-3 3446
14
Memantine Approved, Investigational Phase 4,Phase 2 19982-08-2 4054
15
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 83-43-2 6741
16
Natalizumab Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 189261-10-7
17
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 50-24-8 5755
18
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
19 Potassium Channel Blockers Phase 4,Phase 3
20 Anti-Bacterial Agents Phase 4
21 Antibiotics, Antitubercular Phase 4
22 Antifungal Agents Phase 4
23 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2
24 Calcineurin Inhibitors Phase 4,Phase 2
25 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
26 Pharmaceutical Solutions Phase 4,Phase 2,Phase 1
27 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2
28 Antiviral Agents Phase 4,Phase 3,Phase 1,Phase 2
29 Interferon-beta Phase 4,Phase 3,Phase 2,Phase 1
30 interferons Phase 4,Phase 3,Phase 2,Phase 1
31 Analgesics Phase 4,Phase 1,Phase 2
32 Dopamine Agents Phase 4,Phase 2,Phase 1
33 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
34 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 1,Phase 2
35 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 1,Phase 2
36 Dermatologic Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
37 Anti-Anxiety Agents Phase 4,Phase 2
38 Anticonvulsants Phase 4,Phase 3,Phase 2
39 Antimanic Agents Phase 4,Phase 1,Phase 2
40 Antiparkinson Agents Phase 4,Phase 2
41 calcium channel blockers Phase 4,Phase 2
42 Calcium, Dietary Phase 4,Phase 2
43 Central Nervous System Depressants Phase 4,Phase 1,Phase 2
44 Excitatory Amino Acid Antagonists Phase 4,Phase 3,Phase 2
45 Excitatory Amino Acids Phase 4,Phase 3,Phase 2
46 GABA Agents Phase 4,Phase 2
47
gamma-Aminobutyric Acid Phase 4,Phase 2 56-12-2 119
48 Psychotropic Drugs Phase 4,Phase 1,Phase 2
49 Tranquilizing Agents Phase 4,Phase 1,Phase 2
50 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 199)
id Name Status NCT ID Phase
1 Resistance Training and Amino Pyridine in Multiple Sclerosis Unknown status NCT02143167 Phase 4
2 Kidney Biopsy Controlled Trial of Calcineurin Inhibitor Withdrawal Unknown status NCT00896012 Phase 4
3 Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers Completed NCT02683863 Phase 4
4 Open-Label Safety Extension Study of Avonex Completed NCT00915460 Phase 4
5 Effect of Interferon Beta-1a (Avonex®) on Changes of Non-Conventional MRI Measures in Patients With MS Completed NCT00463710 Phase 4
6 Follow-up Study After 11 Years of Patients Who Were Included in the BENEFIT Trial (304747) With a First Demyelinating Event Suggestive of Multiple Sclerosis Completed NCT01795872 Phase 4
7 Treatment of Pendular Nystagmus in OPT Completed NCT02466191 Phase 4
8 Methylprednisolone During the Switch Between Natalizumab and Fingolimod Recruiting NCT02769689 Phase 4
9 Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS) Recruiting NCT02739542 Phase 4
10 A Double Blind, Randomized, Placebo Controlled, Crossover Study of the Effectiveness of Oral Fampridine in Improving Upper Limb Function in Progressive Multiple Sclerosis Active, not recruiting NCT02208050 Phase 4
11 Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients Active, not recruiting NCT03092544 Phase 4
12 Safety and Effectiveness of Switching Relapsing MS Patients Treated With Natalizumab at Risk for PML to Teriflunomide Active, not recruiting NCT01970410 Phase 4
13 Oral Prednisone Taper Versus Placebo for the Treatment of Acute Relapses in Multiple Sclerosis Terminated NCT01411514 Phase 4
14 Natalizumab De-escalation to Interferon-beta-1b in Patients With Relapsing-remitting Multiple Sclerosis Terminated NCT01701856 Phase 4
15 The Efficacy of EMDR in Patients With PTSD in Multiple Sclerosis Unknown status NCT01743664 Phase 3
16 FTY720 in Patients With Primary Progressive Multiple Sclerosis Completed NCT00731692 Phase 3
17 A Study to Evaluate the Safety and Efficacy of Rituximab in Adults With Primary Progressive Multiple Sclerosis Completed NCT00087529 Phase 2, Phase 3
18 Neurophysiological Study of Sativex in Multiple Sclerosis (MS) Spasticity Completed NCT01538225 Phase 3
19 Sunphenon in Progressive Forms of Multiple Sclerosis Completed NCT00799890 Phase 2, Phase 3
20 A Safety and Efficacy Study of Oral Prolonged-Release Fampridine (BIIB041) in Japanese Participants With Multiple Sclerosis Completed NCT01917019 Phase 3
21 Efficacy of Cyclophosphamide Versus Methylprednisolone in Patients With Secondary Progressive Multiple Sclerosis Completed NCT00241254 Phase 3
22 Lipoic Acid for Secondary Progressive Multiple Sclerosis (MS) Completed NCT01188811 Phase 2, Phase 3
23 Study of Teriflunomide in Reducing the Frequency of Relapses and Accumulation of Disability in Patients With Multiple Sclerosis Completed NCT00134563 Phase 3
24 Expiratory Muscle Training for Persons With Neurodegenerative Disease Completed NCT00856518 Phase 2, Phase 3
25 Progression Rate of MSA Under EGCG Supplementation as Anti-Aggregation-Approach Completed NCT02008721 Phase 3
26 Study to Explore the Mechanism of Action of Ocrelizumab and B-Cell Biology in Participants With Relapsing Multiple Sclerosis (RMS) or Primary Progressive Multiple Sclerosis (PPMS) Recruiting NCT02688985 Phase 3
27 A Phase 3 Study to Compare Efficacy and Safety of Masitinib to Placebo in the Treatment of Patients With Primary Progressive or Relapse-free Secondary Progressive Multiple Sclerosis Recruiting NCT01433497 Phase 2, Phase 3
28 Effect of MD1003 in Progressive Multiple Sclerosis (SPI2) Recruiting NCT02936037 Phase 3
29 A Task-oriented Circuit Training in Multiple Sclerosis Recruiting NCT02421744 Phase 3
30 A Study of Ocrelizumab in Participants With Primary Progressive Multiple Sclerosis Active, not recruiting NCT01194570 Phase 3
31 Effect of MD1003 in Chronic Visual Loss Related to Optic Neuritis in Multiple Sclerosis Active, not recruiting NCT02220244 Phase 3
32 Effect of MD1003 in Spinal Progressive Multiple Sclerosis Active, not recruiting NCT02220933 Phase 3
33 Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study Active, not recruiting NCT00273364 Phase 3
34 Effects of Acthar on Recovery From Cognitive Relapses in MS Enrolling by invitation NCT02290444 Phase 3
35 A Study of NeuroVax™, a Therapeutic TCR Peptide Vaccine for SPMS of Multiple Sclerosis Not yet recruiting NCT02057159 Phase 2, Phase 3
36 Multi-center, Interventional, Phase 3, Randomized, Double-blinded Study of Treatment:Teriflunomide®, in Radiologically Isolated Syndrome Not yet recruiting NCT03122652 Phase 3
37 Hydroxyurea in Primary Progressive Multiple Sclerosis Terminated NCT01103583 Phase 2, Phase 3
38 A Clinical Study of the Efficacy of Natalizumab on Reducing Disability Progression in Participants With Secondary Progressive Multiple Sclerosis Terminated NCT01416181 Phase 3
39 BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis Terminated NCT02430532 Phase 3
40 Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis Terminated NCT00468611 Phase 3
41 Alfuzosin for Voiding Dysfunction in Multiple Sclerosis (MS) Terminated NCT00688948 Phase 2, Phase 3
42 Neuroprotection and Natural History in Parkinson's Plus Syndromes (NNIPPS) Terminated NCT00211224 Phase 3
43 Efficacy, Safety and Tolerability of Andrographolides Versus Placebo in Patients With Progressive Forms of MS Unknown status NCT02273635 Phase 1, Phase 2
44 The Effects of Erythropoietin on Clinical Disability and Brain Pathology in Patients With Progressive Multiple Sclerosis Unknown status NCT01144117 Phase 2
45 AIMSPRO in the Treatment of Bladder Dysfunction in Secondary Progressive Multiple Sclerosis Unknown status NCT01228396 Phase 2
46 Mesenchymal Stem Cells for the Treatment of MS Unknown status NCT00781872 Phase 1, Phase 2
47 Combination Therapy of Betaseron-Prograf in Multiple Sclerosis Unknown status NCT00298662 Phase 2
48 Autologous Mesenchymal Stem Cells for the Treatment of Neuromyelitis Optica Spectrum Disorders Unknown status NCT02249676 Phase 2
49 Use of Cannabinoids in Patients With Multiple Sclerosis Unknown status NCT00202423 Phase 2
50 Transcranial Direct Current Stimulation as a Novel Therapeutic Approach in Amyotrophic Lateral Sclerosis Unknown status NCT01569958 Phase 2

Search NIH Clinical Center for Primary Progressive Multiple Sclerosis

Genetic Tests for Primary Progressive Multiple Sclerosis

Anatomical Context for Primary Progressive Multiple Sclerosis

MalaCards organs/tissues related to Primary Progressive Multiple Sclerosis:

39
Brain, Lymph Node, Spinal Cord

Publications for Primary Progressive Multiple Sclerosis

Articles related to Primary Progressive Multiple Sclerosis:

(show top 50) (show all 69)
id Title Authors Year
1
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis. ( 28002688 )
2017
2
CSF1R-related leukoencephalopathy mimicking primary progressive multiple sclerosis. ( 27314966 )
2016
3
Cognitive impairment and magnetic resonance imaging correlates in primary progressive multiple sclerosis. ( 27778334 )
2016
4
A significant decrease in diagnosis of primary progressive multiple sclerosis: A cohort study. ( 27072687 )
2016
5
Anti-inflammatory nutritional intervention in patients with relapsing-remitting and primary-progressive multiple sclerosis: A pilot study. ( 26785711 )
2016
6
Primary Progressive Multiple Sclerosis Evolving From Radiologically Isolated Syndrome. ( 26599831 )
2016
7
Primary progressive multiple sclerosis: current therapeutic strategies and future perspectives. ( 27813441 )
2016
8
Anti-SPAG16 antibodies in primary progressive multiple sclerosis are associated with an elevated progression index. ( 26706657 )
2016
9
Primary progressive multiple sclerosis--why we are failing. ( 26827076 )
2016
10
Retinal degeneration in primary-progressive multiple sclerosis: A role for cortical lesions? ( 26993116 )
2016
11
Two cases of relapses in primary progressive multiple sclerosis after fingolimod withdrawal. ( 27159986 )
2016
12
Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial. ( 26827074 )
2016
13
Multimodal neurophysiological evaluation of primary progressive multiple sclerosis - An increasingly valid biomarker, with limits. ( 26590670 )
2015
14
Association of Deep Gray Matter Damage With Cortical and Spinal Cord Degeneration in Primary Progressive Multiple Sclerosis. ( 26457955 )
2015
15
Evaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic Review. ( 26393519 )
2015
16
Analysis of genes, pathways and networks involved in disease severity and age at onset in primary-progressive multiple sclerosis. ( 25583839 )
2015
17
Gray Matter Correlates of Cognitive Performance Differ between Relapsing-Remitting and Primary-Progressive Multiple Sclerosis. ( 26485710 )
2015
18
Brain atrophy and physical disability in primary progressive multiple sclerosis: A volumetric study. ( 26246109 )
2015
19
Melatonin treatment improves primary progressive multiple sclerosis: a case report. ( 25546814 )
2015
20
Paroxetine-Related Adult-Onset Tic Disorder: A Presentation of Primary Progressive Multiple Sclerosis. ( 26222974 )
2015
21
Lack of efficacy of mitoxantrone in primary progressive Multiple Sclerosis irrespective of pharmacogenetic factors: a multi-center, retrospective analysis. ( 25468777 )
2015
22
Brain-Specific Cytoskeletal Damage Markers in Cerebrospinal Fluid: Is There a Common Pattern between Amyotrophic Lateral Sclerosis and Primary Progressive Multiple Sclerosis? ( 26263977 )
2015
23
Evidence for early neurodegeneration in the cervical cord of patients with primary progressive multiple sclerosis. ( 25863355 )
2015
24
Cognitive impairment in a population-based study of patients with multiple sclerosis: differences between late relapsing-remitting, secondary progressive and primary progressive multiple sclerosis. ( 25903918 )
2015
25
Risk Factors Associated with the Onset of Relapsing-Remitting and Primary Progressive Multiple Sclerosis: A Systematic Review. ( 25802867 )
2015
26
PDE7 inhibitor TC3.6 ameliorates symptomatology in a model of primary progressive multiple sclerosis. ( 25994655 )
2015
27
Retraction notice: Language abilities of patients with primary progressive multiple sclerosis: A preliminary group and case investigation. ( 24766406 )
2014
28
Validating predictors of disease progression in a large cohort of primary-progressive multiple sclerosis based on a systematic literature review. ( 24651401 )
2014
29
Hereditary diffuse leukoencephalopathy with spheroids with phenotype of primary progressive multiple sclerosis. ( 25311247 )
2014
30
Levels of soluble TNF-RII are increased in serum of patients with primary progressive multiple sclerosis. ( 24794503 )
2014
31
Genetics of primary progressive multiple sclerosis. ( 24507520 )
2014
32
Modelling the natural history of primary progressive multiple sclerosis. ( 24828900 )
2014
33
Epstein-barr virus in the central nervous system and cervical lymph node of a patient with primary progressive multiple sclerosis. ( 24918642 )
2014
34
Temporal and spatial evolution of grey matter atrophy in primary progressive multiple sclerosis. ( 24099844 )
2014
35
Adult-onset vanishing white matter disease as differential diagnosis of primary progressive multiple sclerosis: A case report. ( 25135182 )
2014
36
Electrophysiological markers and predictors of the disease course in primary progressive multiple sclerosis. ( 23756680 )
2014
37
Efficient generation of myelinating oligodendrocytes from primary progressive multiple sclerosis patients by induced pluripotent stem cells. ( 25254339 )
2014
38
Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis. ( 24909126 )
2014
39
A new CSF1R mutation presenting with an extensive white matter lesion mimicking primary progressive multiple sclerosis. ( 24034409 )
2013
40
Decreased circulating miRNA levels in patients with primary progressive multiple sclerosis. ( 24277735 )
2013
41
Treatment of primary progressive multiple sclerosis. ( 23709215 )
2013
42
A new model for primary-progressive multiple sclerosis? ( 24036552 )
2013
43
Possible new modifications for the McDonald 2010 criteria for the diagnosis of primary progressive multiple sclerosis. ( 23818017 )
2013
44
Characteristic cerebrospinal fluid cytokine/chemokine profiles in neuromyelitis optica, relapsing remitting or primary progressive multiple sclerosis. ( 23637915 )
2013
45
A case of hereditary diffuse leukoencephalopathy with axonal spheroids caused by a de novo mutation in CSF1R masquerading as primary progressive multiple sclerosis. ( 23698128 )
2013
46
Opposite roles of NMDA receptors in relapsing and primary progressive multiple sclerosis. ( 23840674 )
2013
47
Heterozygous X-linked adrenoleukodystrophy-associated myelopathy mimicking primary progressive multiple sclerosis. ( 20803344 )
2011
48
No association between genetic polymorphism at codon 129 of the prion protein gene and primary progressive multiple sclerosis. ( 21320996 )
2011
49
Progranulin gene variability increases the risk for primary progressive multiple sclerosis in males. ( 20463744 )
2010
50
Lack of replication of KIF1B gene in an Italian primary progressive multiple sclerosis cohort. ( 20067515 )
2010

Variations for Primary Progressive Multiple Sclerosis

Expression for Primary Progressive Multiple Sclerosis

Search GEO for disease gene expression data for Primary Progressive Multiple Sclerosis.

Pathways for Primary Progressive Multiple Sclerosis

Pathways related to Primary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

(show all 28)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.85 CSF1R ICAM1 IFNB1 IL10 IL7R MMP9
2
Show member pathways
13.15 CSF1R ICAM1 IFNB1 IL10 IL7R MMP9
3 12.03 IL10 PLP1 TNF
4
Show member pathways
12 IFNB1 IL10 TNF
5 11.95 ICAM1 MMP9 TNF VCAM1
6 11.89 CSF1R IFNB1 TNF
7 11.84 IL10 IL7R TNF
8 11.81 ICAM1 MMP9 VCAM1
9 11.81 ICAM1 MMP9 TNF VCAM1
10 11.76 ICAM1 TNF VCAM1
11 11.74 CSF1R IL7R TNF
12 11.73 ICAM1 MBP MMP9 OMG TNF
13 11.72 ICAM1 TNF VCAM1
14 11.64 IL10 IL7R TNF
15 11.55 ICAM1 IL10 TNF VCAM1
16
Show member pathways
11.47 ICAM1 MMP9 TNF VCAM1
17 11.41 ICAM1 IL10 MMP9 TNF VCAM1
18 11.4 ICAM1 IL10 TNF
19 11.38 ICAM1 MMP9 TNF
20 11.31 ICAM1 IL10 TNF VCAM1
21 11.15 IFNB1 IL10 TNF
22 11.03 ICAM1 MMP9
23 11.01 IFNB1 TNF
24 11 ICAM1 IL10 TNF VCAM1
25 10.97 TNF VCAM1
26 10.9 CSF1R IFNB1 IL10 IL7R TNF
27 10.84 ICAM1 TNF VCAM1
28 10.45 MBP PLP1

GO Terms for Primary Progressive Multiple Sclerosis

Cellular components related to Primary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 9.26 ICAM1 IL7R TNF VCAM1
2 extracellular space GO:0005615 9.23 ICAM1 IFNB1 IL10 MMP9 OMG S100B

Biological processes related to Primary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

(show all 23)
id Name GO ID Score Top Affiliating Genes
1 inflammatory response GO:0006954 9.88 CSF1R IL10 PLP1 TNF
2 positive regulation of protein phosphorylation GO:0001934 9.78 CSF1R MMP9 TNF
3 regulation of cell shape GO:0008360 9.77 CSF1R ICAM1 S100B
4 central nervous system development GO:0007417 9.75 MBP MOG S100B
5 cellular response to lipopolysaccharide GO:0071222 9.74 ICAM1 IL10 TNF
6 extracellular matrix organization GO:0030198 9.67 ICAM1 MMP9 TNF VCAM1
7 response to glucocorticoid GO:0051384 9.63 IL10 S100B TNF
8 leukocyte cell-cell adhesion GO:0007159 9.61 ICAM1 VCAM1
9 B cell differentiation GO:0030183 9.61 IFNB1 IL10 VCAM1
10 osteoclast differentiation GO:0030316 9.6 CSF1R TNF
11 macrophage differentiation GO:0030225 9.56 CSF1R MMP9
12 negative regulation of growth of symbiont in host GO:0044130 9.55 IL10 TNF
13 leukocyte tethering or rolling GO:0050901 9.54 TNF VCAM1
14 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.52 IL10 TNF
15 negative regulation of heterotypic cell-cell adhesion GO:0034115 9.51 IL10 MBP
16 endothelial cell apoptotic process GO:0072577 9.49 IL10 TNF
17 axon ensheathment GO:0008366 9.48 MBP PLP1
18 negative regulation of cytokine secretion involved in immune response GO:0002740 9.4 IL10 TNF
19 membrane to membrane docking GO:0022614 9.32 ICAM1 VCAM1
20 receptor biosynthetic process GO:0032800 9.26 IL10 TNF
21 positive regulation of leukocyte adhesion to vascular endothelial cell GO:1904996 9.16 ICAM1 TNF
22 B cell proliferation GO:0042100 9.13 IFNB1 IL10 IL7R
23 positive regulation of vascular smooth muscle cell proliferation GO:1904707 8.8 IL10 MMP9 TNF

Molecular functions related to Primary Progressive Multiple Sclerosis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 structural constituent of myelin sheath GO:0019911 8.62 MBP PLP1

Sources for Primary Progressive Multiple Sclerosis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....